In­sid­ers: The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

Im­age: Bio­gen CEO Michel Vounatsos at the com­pa­ny’s of­fices in Cam­bridge, MA on Jan. 3, 2017. The Boston Globe via Get­ty

Some of the most in­ter­est­ing on­go­ing dis­cus­sions in biotech are fo­cused on a few key points: how do you cre­ate val­ue, which com­pa­nies are cre­at­ing the great­est val­ue and where is the next Bio­gen or Cel­gene com­ing from?

This piece is for all of you who care to know more about that.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER